1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1111/j.1365-2044.2004.03674.x" target="_blank" rel="noreferrer">http://doi.org/10.1111/j.1365-2044.2004.03674.x</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies
Publisher
An entity responsible for making the resource available
Anaesthesia
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
Subject
The topic of the resource
Female; Humans; Male; Adult; Analgesics; Aged; Middle Aged; Treatment Outcome; Patient Selection; Double-Blind Method; Cross-Over Studies; Chronic disease; Administration; Pain/drug therapy; Drug Combinations; Sleep/drug effects; Pain Measurement/methods; Sublingual; Cannabidiol/adverse effects/therapeutic use; Depressive Disorder/drug therapy; Multiple Sclerosis/drug therapy; Non-Narcotic/adverse effects/therapeutic use; Tetrahydrocannabinol/adverse effects/therapeutic use
Creator
An entity primarily responsible for making the resource
Notcutt W; Price M; Miller R; Newport S; Phillips C; Simmons S; Sansom C
Description
An account of the resource
Three Cannabis Based Medicinal Extracts (CBMEs) for sublingual use became available in 2000. A total of 34 'N of 1' studies were undertaken using this novel therapy for patients with chronic, mainly neuropathic, pain and associated symptoms to explore efficacy, tolerability, safety and dosages. Three CBMEs (Delta9 Tetrahydrocannabinol (THC), Cannabidiol (CBD) and a 1:1 mixture of them both) were given over a 12-week period. After an initial open-label period, the CBMEs were used in a randomised, double-blind, placebo controlled, crossover trial. Extracts which contained THC proved most effective in symptom control. Regimens for the use of the sublingual spray emerged and a wide range of dosing requirements was observed. Side-effects were common, reflecting a learning curve for both patient and study team. These were generally acceptable and little different to those seen when other psycho-active agents are used for chronic pain. These initial experiences with CBME open the way to more detailed and extensive studies.
2004
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1111/j.1365-2044.2004.03674.x" target="_blank" rel="noreferrer">10.1111/j.1365-2044.2004.03674.x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2004
Administration
Adult
Aged
Anaesthesia
Analgesics
Backlog
Cannabidiol/adverse effects/therapeutic use
Chronic Disease
Cross-Over Studies
Depressive Disorder/drug therapy
Double-Blind Method
Drug Combinations
Female
Humans
Journal Article
Male
Middle Aged
Miller R
Multiple Sclerosis/drug therapy
Newport S
Non-Narcotic/adverse effects/therapeutic use
Notcutt W
Pain Measurement/methods
Pain/drug Therapy
Patient Selection
Phillips C
Price M
Sansom C
Simmons S
Sleep/drug effects
Sublingual
Tetrahydrocannabinol/adverse effects/therapeutic use
Treatment Outcome